We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » NICE Says ‘No’ to Opdivo for Renal Cell Carcinoma
The UK’s National Institute for Health and Care Excellence declined to recommend Bristol-Myers Squibb’s Opdivo for reimbursement in the treatment of advanced renal cell carcinoma.